Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS (cyclosporine ophthalmic emulsion) 0.05%.
Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
According to IQVIA, the US market for cyclosporine ophthalmic emulsion generated sales of approximately USD1.9bn in the 12 months from February 2025 to January 2026.
Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product in January 2026.
Kither Biotech completes Phase 1 KIT2014 clinical study
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
FDA grants rare paediatric disease designation to RedHill's opaganib
Antengene presents first ATG-207 preclinical data at EULAR 2026
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline